Nonspecific interstitial pneumonia (NSIP) is often curable, but the answer depends on which type you have. If the inflammation in your lungs hasn’t yet caused permanent scarring, treatment can fully resolve the disease. If scarring has already developed, the goal shifts from cure to slowing progression and preserving lung function, though the outlook is still significantly better than for many other forms of lung fibrosis.
The Two Types Determine Your Outlook
NSIP comes in two forms, and the distinction between them is the single biggest factor in whether a cure is realistic.
Cellular NSIP is the inflammatory form. The lung tissue is inflamed but not yet scarred. This type responds well to treatment and has a five-year survival rate of 100%. Many people with cellular NSIP recover fully and can eventually stop medication, though this process takes months of treatment and follow-up.
Fibrotic NSIP involves scarring (fibrosis) that has replaced healthy lung tissue. Scar tissue in the lungs is permanent and cannot be reversed by any current medication. However, fibrotic NSIP is not a death sentence. A large study of 204 patients with biopsy-confirmed fibrotic NSIP found one-year, five-year, and ten-year survival rates of 100%, 94.6%, and 90.4%, respectively. That’s far better than idiopathic pulmonary fibrosis (IPF), a related condition where median survival is only three to five years. Fibrotic NSIP also responds to anti-inflammatory treatment, which IPF generally does not.
How Treatment Works
The standard first-line treatment is corticosteroids, typically prednisone. The usual approach starts with a moderate-to-high dose for a limited period to bring inflammation under control, then introduces a second medication about eight to ten weeks later so the steroid dose can be gradually reduced. This tapering strategy helps avoid the significant side effects that come with long-term steroid use, including bone loss, weight gain, and elevated blood sugar.
If steroids alone aren’t enough, or if side effects are a concern, doctors add steroid-sparing immunosuppressants as second-line therapy. A third tier of stronger immunosuppressants exists for cases that don’t respond to the first two options. In some situations where the disease isn’t progressing rapidly, a steroid-sparing agent may be used from the start instead of prednisone.
A nationwide study found that treatment led to meaningful lung function improvement after just one year: breathing capacity (FVC) improved by 10%, airflow (FEV1) by 9.8%, and the lungs’ ability to transfer oxygen into the blood improved by 8.4%. Overall, corticosteroid or immunosuppressant therapy helped maintain or improve lung function in 81% of patients with idiopathic NSIP.
Why the Underlying Cause Matters
NSIP doesn’t always appear on its own. It frequently develops alongside autoimmune and connective tissue diseases like rheumatoid arthritis, lupus, or scleroderma. In these cases, treating the underlying condition is essential to controlling the lung disease. When the autoimmune process driving the inflammation is managed, the NSIP component can stabilize or improve.
That said, secondary NSIP tied to autoimmune conditions often requires ongoing therapy. One study found that when immunosuppressive treatment was stopped, improvements in lung function faded back to baseline within six months, suggesting that prolonged treatment may be necessary to maintain stability. For people with autoimmune-related NSIP, “cured” may be less accurate than “well-controlled on medication,” similar to how autoimmune diseases themselves are managed rather than cured.
NSIP can also be triggered by drug reactions, environmental exposures, or infections. When the offending cause is identified and removed, the inflammation may resolve, sometimes without aggressive treatment.
Stopping Treatment Safely
For people who respond well, the eventual goal is to taper off medication entirely. This is achievable for some, particularly those with cellular NSIP. However, stopping immunosuppressive therapy too quickly or too early carries real risk. In clinically significant lung disease, abruptly halting treatment can trigger an acute flare or rapid disease progression, which can be life-threatening. A gradual, cautious decrease is the standard approach, with the aim of using the lowest effective dose and, when possible, discontinuing entirely.
Complete discontinuation of therapy is possible in some types of interstitial lung disease, but it isn’t always achieved with NSIP. Your doctor will monitor your breathing tests and imaging over time to guide decisions about when and whether to stop.
When NSIP Progresses Despite Treatment
A small percentage of people with fibrotic NSIP experience progressive scarring despite medication. When lung function declines to the point that it significantly limits daily life and doesn’t respond to medical therapy, lung transplantation becomes an option. Fibrotic NSIP is actually the most common non-IPF interstitial lung disease for which transplants are performed.
Transplant outcomes for non-IPF interstitial lung diseases show a one-year conditional survival (for those who survive the initial recovery) of about 91% at three years and 71% at five years. Transplantation is reserved for advanced cases and comes with its own significant long-term challenges, including the need for lifelong anti-rejection medication. But for people with end-stage disease, it can meaningfully extend both life and quality of life.
What Recovery Looks Like in Practice
If you’ve been diagnosed with cellular NSIP, the realistic expectation is that treatment will resolve the inflammation over a period of several months. You’ll likely need regular follow-up visits, breathing tests, and imaging to confirm that the disease is responding. Full recovery is common, though it takes patience.
If you have fibrotic NSIP, the picture is more nuanced. Treatment can halt or slow the scarring, improve your breathing capacity, and keep you stable for years or even decades. The ten-year survival rate above 90% reflects a disease that, while not always curable in the strictest sense, is highly manageable for most people. The key is early diagnosis and consistent treatment, since lung function that’s lost to fibrosis doesn’t come back, but function that’s impaired by active inflammation often does.